Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a Healthcare company (Biotechnology) with a market capitalization of $10.9B. The Maz Rating grades it against the other companies in its sector.
Halozyme Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $95.97, Halozyme Therapeutics, Inc. trades at 22.8x trailing earnings and 6.1x sales, with an EV/EBITDA of 16.3. Over the last twelve months it generated about $1.8B of revenue and $479M of net income. It runs a gross margin of 82.3%, an operating margin of 55.9% and a net margin of 26.9%. It shows return on equity of 544.3%, return on invested capital of 22.6% and a free cash flow yield of 8.1%. On the balance sheet: a debt-to-equity ratio of -58.84 and a current ratio of 3.88. Over the past 52 weeks the share price ranged from $61.23 to $134.00, with a beta of 0.90.
Halozyme Therapeutics, Inc. does not currently pay a dividend.
27 Wall Street analyst ratings cover the stock: 16 Buy, 10 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.